MedTrace Logo

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

NCT00953498 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-09-02

No results posted yet for this study

Summary

HDL from patients with type 2 diabetes show a significant reduction of their endothelium-dependent vasodilatory effect.

The primary objective of the study is to analyze whether treatment with glitazones (pioglitazone and rosiglitazone)may improve the endothelium-dependent vasodilatory effect of HDL lipoproteins in patients with type 2 diabetes.

The secondary objectives are:

* to analyze the effect of glitazone treatment on phospholipase A2
* to look for possible differences between the effects of pioglitazone and those of rosiglitazone
* to analyze the glycemic response to glitazone therapy according to clinical and biological baseline characteristics.

Conditions

Interventions

DRUG

pioglitazone

After randomization, patients will be treated by pioglitazone or rosiglitazone

DRUG

rosiglitazone

treatment with rosiglitazone at a dose between 4mg and 8 mg/day

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Principal Investigators

  • Bruno L Vergès, MD,PhD · CHU Dijon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953498 on ClinicalTrials.gov